当前位置:APASL-en-亚太肝脏研究协会年会 >> 正文
[APASL2014]Entecavir for CHB: A Chinese Clinical Perspective
—— 作者:J.L.Hou 时间:2014-03-19
阅读数:
99
简介:In a 5-year, longitudinal study assessing the efficacy of entecavir (ETV) versus other standard-or-care therapies, Dr. Hou and colleagues revealed that ETV therapy resulted in a 85% virological response, compared with 67% overall with all other treatments.
请登录后查看详细内容
标签:
摘要赏析
摘要赏析
乙肝
发表评论
全部评论